A Phase IIa, Double-Blind, Randomized, Parallel Group, Placebo-Controlled Multi-Centre Study to Evaluate the Effect of AZD8154 Administered via Nebulizer Once Daily on Allergen-Induced Inflammation in Subjects with Mild Allergic Asthma Challenged with an Inhaled Allergen
AZD8154 nebulizer suspension, 20 mg/mL, Placebo
18 Years - 65 Years
Endpoint Classification: -
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Verified 01 Nov 2020 by AstraZeneca
No locations available
Subjects will receive AZD8154 QD dosing for 10 days
Drug: AZD8154 nebulizer suspension, 20 mg/mL
Subjects will receive AZD8154 from Day 1 to Day 10 (10 consecutive days) by using nebulizer and dosimeter system as inhaled dosing and delivered dose will be 3mg.
|Placebo Comparator: Placebo|
Subjects will receive AZD8154 matching placebo QD dosing for 10 days
Subjects will receive AZD8154 matching placebo (placebo nebulizer suspension, glucose solution for infusion 50 mg/mL) QD from Day 1 to Day 10 (10 consecutive days) by using nebulizer and dosimeter system as inhaled dosing.